Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

aceutical research and development company. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA.

For further information on Tibotec, please visit www.tibotec.com

Safe Harbor Statement

This press release my contain forward-looking statements, including statements that (i) PROVE 1 data support potential to shorten treatment duration and increase SVR rates in patients with genotype 1 HCV infection; (ii) 12 weeks of telaprevir-based therapy enabled some patients to clear the virus; (iii) high SVR rates with telaprevir may be achieved with regimens that are no longer than 24 weeks in duration; (iv) interim results support our approach to evaluating telaprevir-based regimens of differing durations in our Phase 2 program; (v) the information from PROVE 1 and PROVE 2 will allow us to design optimized durations and regimens for Phase 3 development; (vi) the PROVE studies are expected to provide information to optimize treatment duration and treatment regimen for telaprevir-based therapy; (vii) Vertex will consider evaluation of treatment regimens that would include telaprevir in combination with peg-IFN and RBV, and depending on PROVE 2 data, regimens that may exclude RBV; (viii) Vertex expects to focus on treatment durations of no more than 24 weeks; and (ix) Vertex and Tibotec are planning to meet with regulatory authorities to discuss the Phase 3 design in mid-2007 and are planning to initiate Phase 3 clinical development in the fourth quarter of 2007. While management makes its best efforts to be accurate in making forward-looking statements, such statements are subject to risks and uncertainties that could cause the actual results of studies to vary materially. Those risks and uncertainties include, among other things, the risk that observed outcomes in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Havel,s market leading EchoStim® Echogenic Insulated needle has ... Peripheral Nerve Blocks (PNBs) using nerve stimulation and ... improved needle has more, brighter, easier to see ... inexperienced practitioners the benefits of using both nerve ...
... 12, 2011 The association representing Montana,s providers of ... bill in Congress to repeal the controversial Medicare "competitive" ... "It is imperative that H.R. 1041 pass ... Medicare patients and local businesses in Montana," said Mike ...
Cached Medicine Technology:Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... Management Team and Board of Directors , ... Company,s VisionCHERRY HILL, N.J., March 18 eFoodSafety.com, Inc. ... company with a portfolio of aesthetic, dermatology, environmental and ... name from eFoodSafety.com, Inc. to Nuvilex, Inc. The Company ...
... software provider , is launching a new website. The website ... in-depth understanding of EMR-integrated services Also featured are an email ... , ... Little Rock, AR (PRWeb) March 18, 2009 ...
... EXTON, Pa., March 18 Kensey Nash Corporation (Nasdaq: ... has approved a stock repurchase. The new program allows ... of its issued and outstanding shares of Common Stock and ... the repurchases using its available cash. "Given our strong cash ...
... YORK, March 18 The Dirty Secrets ... products labeled "fragrance free" may actually contain chemicals to ... pollute the air in your home with harmful chemicals. ... about common spring cleaning hazards and how to avoid ...
... SAN FRANCISCO, March 18 The Women,s Dermatologic ... announces the 2009-2010 presidency of Wendy E. Roberts, ... Annual Meeting Luncheon held recently in conjunction with the ... Suzanne M. Connolly, MD , served as WDS ...
... Patient,s Own Stem Cells to Be Harvested and Transplanted ... Permanent Dental ImplantationRANCHO SANTA MARGARITA, Calif., March 18 ... infectious grin, but to attach an implant would be ... in his jaw. Dr. Ivan Ho, a Southern ...
Cached Medicine News:Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 2Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 3Health News:eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company 4Health News:New Electronic Medical Transcription Company Website Arrives 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:Five Hot Show Ideas for Spring-Related Topics 2Health News:Wendy E. Roberts, MD, Named 2009-2010 President of the Women's Dermatologic Society 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 2Health News:Southern California Dentist First on the West Coast to Perform Concentrated Stem Cell Transplant for Dental Implant Procedure 3
... Portex® Blue Line ULTRA® Suctionaid® tracheostomy tubes ... removal of secretions from above the tracheostomy ... ULTRA® Suctionaid® tracheostomy tubes provide an additional ... from above the tracheostomy tube cuff helping ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
... For additional patient safety, the ... an integral 15 mm ISO ... to a ventilator, with or ... place , ,Portex® laryngectomy ...
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
Medicine Products: